<?xml version="1.0" encoding="ASCII"?>
<biogps><data><item key="owner">ArrayExpress Uploader</item><item key="pop_total">0</item><item key="species">human</item><item key="factors"><item><item key="GSE16155GSM404936"/></item><item><item key="GSE16155GSM404937"/></item><item><item key="GSE16155GSM404938"/></item><item><item key="GSE16155GSM404939"/></item><item><item key="GSE16155GSM404940"/></item><item><item key="GSE16155GSM404941"/></item><item><item key="GSE16155GSM404942"/></item><item><item key="GSE16155GSM404943"/></item><item><item key="GSE16155GSM404944"/></item><item><item key="GSE16155GSM404945"/></item><item><item key="GSE16155GSM404946"/></item><item><item key="GSE16155GSM404947"/></item><item><item key="GSE16155GSM404948"/></item><item><item key="GSE16155GSM404949"/></item><item><item key="GSE16155GSM404950"/></item><item><item key="GSE16155GSM404951"/></item><item><item key="GSE16155GSM404952"/></item><item><item key="GSE16155GSM404953"/></item><item><item key="GSE16155GSM404954"/></item></item><item key="id">3283</item><item key="ownerprofile_id">arrayexpress_sid</item><item key="platform">4</item><item key="summary_wrapped">Ependymoma, the 3rd most common brain tumor in children, recurs in approximately 50% of patients. There is currently no robust marker...</item><item key="geo_gse_id">E-GEOD-16155</item><item key="owner_profile">/profile/8773/arrayexpressuploader</item><item key="factor_count">0</item><item key="sample_count">19</item><item key="tags"><item>brain</item></item><item key="lastmodified">Dec.12, 2014</item><item key="is_default">False</item><item key="geo_gds_id"/><item key="slug">transcription-profiling-of-human-ependymoma-tumors</item><item key="geo_id_plat">E-GEOD-16155_A-AFFY-44</item><item key="name">Transcription profiling of human ependymoma tumors with known clinical outcomes</item><item key="created">Sep.12, 2014</item><item key="summary">Ependymoma, the 3rd most common brain tumor in children, recurs in approximately 50% of patients. There is currently no robust marker that predicts for recurrence, which is a significant clinical problem; We used global gene expression profiling of 19 patient surgical samples obtained at initial diagnosis and with known clinical outcomes to discover novel prognostic markers. Experiment Overall Design: Gene expression profiles were generated from surgical tumor samples using Affymetrix HG-U133plus2 chips. Profiles were divided into recurrent and non-recurrent groups in order to identify differentially expressed genes that were associated with risk of recurrence. In addition, time to progression was correlated with gene expression as a continuous variable in the recurrent group.</item><item key="source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-16155</item><item key="sample_source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-16155/samples/</item></data></biogps>
